A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma

Singh, 2011, Uveal melanoma: Trends in incidence, treatment, and survival, Ophthalmology, 118, 1881, 10.1016/j.ophtha.2011.01.040

McLaughlin, 2005, Incidence of noncutaneous melanomas in the U.S, Cancer, 103, 1000, 10.1002/cncr.20866

Shields, 2009, Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes, Arch Ophthalmol, 127, 989, 10.1001/archophthalmol.2009.208

Virgili, 2007, Incidence of uveal melanoma in Europe, Ophthalmology, 114, 2309, 10.1016/j.ophtha.2007.01.032

Singh, 2005, Uveal melanoma: Epidemiologic aspects, Ophthalmol Clin North Am, 18, 75, 10.1016/j.ohc.2004.07.002

Eskelin, 2002, Mode of presentation and time to treatment of uveal melanoma in Finland, Br J Ophthalmol, 86, 333, 10.1136/bjo.86.3.333

Bergman, 2005, Ruthenium brachytherapy for uveal melanoma, 1979-2003: Survival and functional outcomes in the swedish population, Ophthalmology, 112, 834, 10.1016/j.ophtha.2004.11.038

Virgili, 2008, Survival in patients with uveal melanoma in Europe, Arch Ophthalmol, 126, 1413, 10.1001/archopht.126.10.1413

Garretson, 1987, Choroidal melanoma treatment with iodine 125 brachytherapy, Arch Ophthalmol, 105, 1394, 10.1001/archopht.1987.01060100096035

Packer, 1980, Radiotherapy of choroidal melanoma with iodine 125, Int Ophthalmol Clin, 20, 135

Collaborative Ocular Melanoma Study Group, 2006, The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28, Arch Ophthalmol, 124, 1684, 10.1001/archopht.124.12.1684

Diener-West, 2001, The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, iii: Initial mortality findings. COMS report no. 18, Arch Ophthalmol, 119, 969, 10.1001/archopht.119.7.969

Sieving, 2001, Fifteen years of work: The COMS outcomes for medium-sized choroidal melanoma, Arch Ophthalmol, 119, 1067, 10.1001/archopht.119.7.1067

Rivard, 2004, Update of AAPM task group no. 43 report: A revised AAPM protocol for brachytherapy dose calculations, Med Phys, 31, 633, 10.1118/1.1646040

Sealy, 1980, Progress in the use of iodine therapy for tumours of the eye, Br J Radiol, 53, 1052, 10.1259/0007-1285-53-635-1052

Fontanesi, 1993, Treatment of choroidal melanoma with i-125 plaque, Int J Radiat Oncol Biol Phys, 26, 619, 10.1016/0360-3016(93)90278-4

Melia, 2001, Collaborative ocular melanoma study (COMS) randomized trial of i-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16, Ophthalmology, 108, 348, 10.1016/S0161-6420(00)00526-1

Wilkinson, 2008, Dosimetric comparison of 106Ru and 125I plaques for treatment of shallow (<or=5 mm) choroidal melanoma lesions, Br J Radiol, 81, 784, 10.1259/bjr/76813976

Takiar, 2014, Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma, Pract Radiat Oncol, 4, e189, 10.1016/j.prro.2013.08.004

Chiu-Tsao, 2012, Dosimetry of (125)i and (103)pd COMS eye plaques for intraocular tumors: Report of task group 129 by theAAPM and ABS, Med Phys, 39, 6161, 10.1118/1.4749933

Collaborative Ocular Melanoma Study Group, 2007, Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the collaborative ocular melanoma study: COMS report no. 27, Ophthalmology, 114, 1363, 10.1016/j.ophtha.2006.10.039